Literature DB >> 19959105

High-resolution typing for unrelated donor transplantation: how far do we go?

Mary M Horowitz1.   

Abstract

For best results with unrelated donor transplantation of acute myeloid leukaemia (AML) patients, high-resolution typing should be completed for human leucocyte antigens (HLAs) A, B, C and DR. In the absence of an HLA-identical sibling, an unrelated adult donor, fully matched or with a single mismatch at these loci, should be used. If such a donor is not available in a timely manner, cord blood mismatched at one or two loci may be used. Data also suggest that peripheral blood transplantation may be more permissive of HLA mismatching than bone marrow transplants. Transplant decisions should be based on several factors, including availability of matched donors, as well as patient age, performance status and disease stage.

Entities:  

Mesh:

Year:  2009        PMID: 19959105      PMCID: PMC2904986          DOI: 10.1016/j.beha.2009.09.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  5 in total

Review 1.  National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants.

Authors:  Robert A Bray; Carolyn K Hurley; Naynesh R Kamani; Ann Woolfrey; Carlheinz Müller; Stephen Spellman; Michelle Setterholm; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

2.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

3.  HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States.

Authors:  Lee Ann Baxter-Lowe; Martin Maiers; Stephen R Spellman; Michael D Haagenson; Tao Wang; Marcelo Fernandez-Vina; Steven G E Marsh; Mary Horowitz; Carolyn Katovich Hurley
Journal:  Biol Blood Marrow Transplant       Date:  2009-08       Impact factor: 5.742

4.  Effect of HLA-A2 allele disparity on clinical outcome in hematopoietic cell transplantation from unrelated donors.

Authors:  Y Morishima; T Kawase; M Malkki; E W Petersdorf
Journal:  Tissue Antigens       Date:  2007-04

Review 5.  Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.

Authors:  Chatchada Karanes; Gene O Nelson; Pintip Chitphakdithai; Edward Agura; Karen K Ballen; Charles D Bolan; David L Porter; Joseph P Uberti; Roberta J King; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2008-09       Impact factor: 5.742

  5 in total
  8 in total

1.  Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

Authors:  Coco de Koning; Julie-Anne Gabelich; Jurgen Langenhorst; Rick Admiraal; Jurgen Kuball; Jaap Jan Boelens; Stefan Nierkens
Journal:  Blood Adv       Date:  2018-03-13

Review 2.  Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

Authors:  Coco de Koning; Rick Admiraal; Stefan Nierkens; Jaap Jan Boelens
Journal:  Stem Cell Investig       Date:  2017-05-16

3.  Targeting an alternate Wilms' tumor antigen 1 peptide bypasses immunoproteasome dependency.

Authors:  Miranda C Lahman; Thomas M Schmitt; Kelly G Paulson; Nathalie Vigneron; Denise Buenrostro; Felecia D Wagener; Valentin Voillet; Lauren Martin; Raphael Gottardo; Jason Bielas; Julie M McElrath; Derek L Stirewalt; Era L Pogosova-Agadjanyan; Cecilia C Yeung; Robert H Pierce; Daniel N Egan; Merav Bar; Paul C Hendrie; Sinéad Kinsella; Aesha Vakil; Jonah Butler; Mary Chaffee; Jonathan Linton; Megan S McAfee; Daniel S Hunter; Marie Bleakley; Anthony Rongvaux; Benoit J Van den Eynde; Aude G Chapuis; Philip D Greenberg
Journal:  Sci Transl Med       Date:  2022-02-09       Impact factor: 19.319

4.  Whole exome sequencing to estimate alloreactivity potential between donors and recipients in stem cell transplantation.

Authors:  Juliana K Sampson; Nihar U Sheth; Vishal N Koparde; Allison F Scalora; Myrna G Serrano; Vladimir Lee; Catherine H Roberts; Max Jameson-Lee; Andrea Ferreira-Gonzalez; Masoud H Manjili; Gregory A Buck; Michael C Neale; Amir A Toor
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

Review 5.  Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

Authors:  Jeannine S McCune; Meagan J Bemer
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

6.  HLA class I (-A, -B, -C) and class II (-DR, -DQ) polymorphism in the Mauritanian population.

Authors:  Cheikh Tijani Hamed; Ghlana Meiloud; Fatimetou Veten; Mouna Hadrami; Sidi M Ghaber; Ely C Boussaty; Norddine Habti; Ahmed Houmeida
Journal:  BMC Med Genet       Date:  2018-01-03       Impact factor: 2.103

7.  Benchmarking the Human Leukocyte Antigen Typing Performance of Three Assays and Seven Next-Generation Sequencing-Based Algorithms.

Authors:  Ping Liu; Minya Yao; Yu Gong; Yunjie Song; Yanan Chen; Yizhou Ye; Xiao Liu; Fugen Li; Hua Dong; Rui Meng; Hao Chen; Aiwen Zheng
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

8.  Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation.

Authors:  Coco de Koning; Weiyang Tao; Amelia Lacna; Karin van Veghel; Mitchell E Horwitz; Guillermo Sanz; Madan H Jagasia; John E Wagner; Patrick J Stiff; Rabi Hanna; Daniela Cilloni; David Valcárcel; Tony Peled; Einat Galamidi Cohen; Uri Goshen; Aridaman Pandit; Caroline A Lindemans; Jaap Jan Boelens; Stefan Nierkens
Journal:  Bone Marrow Transplant       Date:  2021-07-26       Impact factor: 5.174

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.